Association of plasma proteins with rate of cognitive decline and dementia: 20-year follow-up of the Whitehall II and ARIC cohort studies

Joni V. Lindbohm, Nina Mars, Keenan A. Walker, Archana Singh-Manoux, Gill Livingston, Eric J. Brunner, Pyry N. Sipilä, Kalle Saksela, Jane E. Ferrie, Ruth Lovering, Stephen A. Williams, Aroon D. Hingorani, Rebecca F. Gottesman, Henrik Zetterberg, Mika Kivimäki
doi: https://doi.org/10.1101/2020.11.18.20234070

Abstract

The role of circulating proteins in Alzheimer’s disease and related dementias is unknown. Using a follow-up of two decades, 4953 plasma proteins, and discovery (Whitehall II) and replication cohort (ARIC), we examined plasma proteins associated with cognitive decline rate and dementia. After replication and adjustment for known dementia risk factors, fifteen proteins were associated with cognitive decline rate and dementia. None of these were amyloid, tau, or neurofilament-related proteins. Currently approved medications can target five of the proteins. The results support systemic pathogenesis of dementias, may aid in early diagnosis, and suggest potential targets for drug development.

Introduction

Alzheimer’s disease and related dementias pose an increasing challenge with considerable costs to the individual and to health and social care services.1 Until recently, amyloid beta and tau proteins have dominated pathophysiological models of dementia aetiology.2 However, numerous prevention and treatment trials targeting these biomarkers have failed.3, 4 In addition, longitudinal studies suggest that most cognitively normal amyloid-positive people never develop clinical dementia.5 Given this and the high prevalence of mixed types of dementia in the general population, there is a need to expand research on early biomarkers for dementia beyond amyloid and tau.

Causes of dementia are increasingly thought to be systemic.6, 7 Recent development of scalable platforms allows simultaneous assessment thousands of circulating proteins.8, 9 These have the potential to identify drivers of dementia, and move the field beyond amyloid and tau. For several reasons, circulating proteins are promising targets for biomarker and drug discovery. Proteins are regulators and effectors of biological processes and also imprints of the effects of genes, the environment, age, current co-morbidities, behaviours, and medications, all of which may affect dementia development.10 Proteins are also highly druggable as they can be targeted by monoclonal antibodies, small molecule drugs, or proteolysis-targeting chimaeras.11-14 Indeed, of all currently approved medications, approximately 96% target proteins.11 Animal studies also support a causal role of circulating plasma proteins in neurodegeneration. Plasma from young mice, via injection or through parabiosis (joining two animals so they share blood circulation) has been shown to restore memory and stimulate synaptic plasticity in the aged mouse hippocampus.15-17 In humans, multiple circulating proteins have been linked with dementia, but the studies to date have been mainly cross-sectional, based on small samples, or lacked replication.18

In this report from two large cohort studies, the British Whitehall II and the US Atherosclerosis Risk in Communities (ARIC) study, we used SomaScan technology to examine 4953 plasma proteins, including 22 related to amyloid, tau, or neurofilaments, as risk factors for cognitive decline and dementia. To determine what role proteins play in the early stages of neurodegeneration when dementia may still be preventable, we assessed plasma proteins in late middle age and followed subsequent cognitive decline and dementia over two decades. Thus, our study design explicitly takes into consideration the long preclinical phase of dementia.

Results

In the random sample of 2274 participants in the Whitehall II discovery cohort, mean age was 56.1 (SD 5.9) and 1653 (73.0%) were men (Table 1 and Figure 1). During a mean follow-up of 20.4 years, 106 individuals developed dementia (36 were Alzheimer’s, 19 vascular, and 51 mixed or other dementias). Figure 2, part A shows that those who developed dementia had steeper cognitive decline slopes than participants who remained dementia-free. After FDR correction, 246 of the 4953 proteins were associated with increased rate of cognitive decline (Figure 2, part B). None of the amyloid-, tau-, or neurofilament-related proteins were associated with accelerated cognitive decline after FDR correction (Supplementary Table 1 and Supplementary Table 2).

View this table:
Supplementary Table 1.

Hazard ratios between SD increase in amyloid, tau, and neurofilament related protein levels and cognitive decline. None of these survived false discovery rate (FDR) correction of 5%.

View this table:
Supplementary Table 2.

Amyloid, tau, and neurofilament related protein functions, tissue expression, and Gene Ontology terms from UniProt database.

View this table:
Table 1.

Whitehall and ARIC participant characteristics at the time of blood collection for protein measurement. Values are displayed as means (SD) for continuous variables, frequency (column percentages) for categorical variables, and interquartile range (IQR) for follow-up time.

View this table:
Table 2.

Associations between the proteins and dementia related pathologies, existing evidence of these associations, and current medications that can influence protein function or level

Figure 1.
Figure 1.

Flowchart of the study design.

Figure 2.
Figure 2.

Summary of the three steps in protein analysis.

Of the 246 proteins, 21 were also associated with incident dementia in the Whitehall II study (Figure 2, part C). Thus, replication analyses in ARIC were based on 21 proteins. In this cohort, 1942 of the 11 395 participants developed dementia during a mean follow-up of 17.4 years. Fifteen of the 21 proteins associated with cognitive decline and dementia in the Whitehall II study were also associated with dementia in the ARIC cohort (Figure 2, part D) with the hazard ratios ranging between 1.08 and 1.64 in age, sex, and ethnicity/race adjusted analyses.

In additional analyses based on the Whitehall data, the 15 protein-dementia associations changed little after further adjustment for age, sex, ethnicity, SBP, antihypertensive medication, BMI, alcohol consumption, smoking, diabetes, socio-economic, and APOE status (Supplementary Figures 1 and 2) and taking into account competing risk of death (Supplementary Figure 3). A cognitive domain specific analysis suggested that phonemic fluency and executive functioning mostly drove the associations with increased rate of cognitive decline (Supplementary Tables 3-7). There were no strong correlations between the 15 proteins (all correlations ≤|0.53|, Supplementary Figure 4).

Supplementary Figure 1.
Supplementary Figure 1.

Age and sex adjusted results for the 15 proteins associated with both cognitive decline and dementia in the Whitehall II study.

Supplementary Figure 2.
Supplementary Figure 2.

Age, sex, SBP, antihypertensive medication, smoking, diabetes, APOE genotype, BMI, alcohol consumption, and socioeconomic status adjusted results for the 15 proteins associated with both cognitive decline and dementia in the Whitehall II study.

Supplementary Figure 3.
Supplementary Figure 3.

Age, sex, SBP, antihypertensive medication, smoking, diabetes, APOE genotype, BMI, alcohol consumption, and socioeconomic status adjusted results from competing risks (death) model for the 15 proteins associated with both cognitive decline and dementia in the Whitehall II study.

View this table:
Supplementary Table 3.

Associations between the cognitive decline slope and a SD increase in the 15 proteins that survived replication.

View this table:
Supplementary Table 4.

Associations between the memory decline slope and a SD increase in the 15 proteins that survived replication.

View this table:
Supplementary Table 5.

Associations between the phonemic fluency decline slope and a SD increase in the 15 proteins that survived replication.

View this table:
Supplementary Table 6.

Associations between the semantic fluency decline slope and a SD increase in the 15 proteins that survived replication.

View this table:
Supplementary Table 7.

Associations between the executive function decline slope and SD increase in the 15 proteins that survived replication.

Supplementary Figure 4.
Supplementary Figure 4.

Between protein correlations.

The 15 proteins were mostly expressed in tissues other than the brain (Figure 3 and Supplementary Table 8). Of the proteins, 14 were secreted and one was a cell membrane protein. All of them were related to one or more biological systems that are relevant to dementia aetiology: dysfunction of the immune system and blood-brain barrier (BBB), vascular pathology, and central insulin resistance (Table 1). For five proteins, a medication that can influence the protein’s function (NPS-PLA2, CDCP1, and IGFBP-7) or reduce its levels (N-terminal pro-BNP, and OPG) is available. All these medications have passed phase III trials and are used to treat diabetes, inflammatory- or cardiovascular diseases (Supplementary Table 9).

View this table:
Supplementary Table 8.

Protein expression levels in the brain tissue for 15 proteins that survived replication.

View this table:
Supplementary Table 9.

Drugs that can influence proteins associated with dementia, their potential mechanisms of action and current indications.

Figure 3.
Figure 3.

Expression profile in transcripts per million (TPM) of the genes coding the 15 proteins associated with cognitive decline and dementia that survived multivariate adjustment, competing risks, and replication.

Discussion

This study identified 15 plasma proteins that were associated with increased rate of cognitive decline and increased 20-year risk of dementia in the British Whitehall II study. Of these 14 were secreted (N-terminal pro-BNP, CDCP1, MIC-1, CRDL1, RNAS6, SAP3, HE4, TIMP-4, IGFBP-7, OPG, SVEP1, TREM2, NPS-PLA2, MARCKSL1), and one was a cell membrane protein (SIGLEC-7), all mostly expressed outside central nervous system. The associations with dementia were replicated in an independent US cohort study, ARIC; were robust to adjustments for known dementia risk factors, such as hypertension, smoking, diabetes, and APOE status; and were not explained by competing risk of death. Of the 15 proteins, 5 (CDCP1, NPS-PLA2, IGFBP-7, N-terminal pro-BNP, and OPG) are modifiable using existing medications indicated for conditions other than dementias. To our knowledge, this is the largest proteome-wide study with replicated results on the long-term associations between plasma proteins, cognitive decline and risk of dementia.

Our database search on protein expression profiles found that genes encoding the 15 proteins are mainly expressed in tissues other the brain. This suggests that the elevated circulating protein levels in individuals at increased dementia risk are unlikely to represent markers of neurodegeneration resulting from proteins leaking from damaged cells in the central nervous system. In contrast, the expression profiles are consistent with the hypothesis that the identified proteins relate to systemic processes that increase dementia risk.

Of the 15 protein-dementia associations, seven (SVEP1, HE4, CDCP1, SIGLEC-7, MARCKSL1, CRDL1, and RNAS6) are novel, six (SAP3, NPS-PLA2, IGFBP-7, MIC-1, TIMP-4, OPG) have been previously reported in case-control studies19-26 and two (TREM2, N-terminal pro-BNP) in prospective cohort studies,27-29 all showing the same direction as in this study.

Eleven of the proteins (six novel and five previously identified) are associated with immune response (Figures 4A and B). Of these, NPS-PLA2, TREM2, MIC-1, OPG and TIMP-4,21, 24, 25, 27, 30-35 have been considered to increase dementia risk due to involvement in activation, adhesion, survival promotion, and infiltration of neutrophils and macrophages. We identified two additional proteins, SVEP1 and MARCKSL1, which may also act in these processes.36, 37 SVEP1 can also activate the complement system, which, if prolonged, can be detrimental to endothelial cells.38 Leakage of complement through damaged endothelium into the CNS, in turn, can cause the synapse loss in the hippocampus observed in dementia.39 This is supported by a recent consortium-based case-control study that showed an association between complement related sCR1, factor B, and factor H and Alzheimer′s disease.40 The elevated levels of SVEP1 among asymptomatic individuals who developed dementia in the present study suggests that SVEP1 might play a role in abnormal complement activation that predisposes to dementia.41

Figure 4.
Figure 4.
Figure 4.
Figure 4.
Figure 4.
Figure 4.

Dementia-related pathologies for the 15 proteins associated with cognitive decline rate and increased dementia incidence

CDCP1 is a further identified immune-system related protein. It is a ligand for CD6 on T-cells, which upregulates T-cell activation and infiltration, and increases synthesis of pro-inflammatory cytokines.42 According to multiple sclerosis mouse models, anti-CD-6 antibodies ameliorate, and CD6 and CDCP1 knock out protects from encephalomyelitis42 suggesting that higher levels of CDCP1 might predispose to central inflammation. SIGLEC-7 is an inhibitory receptor in NK-cells that recognizes “self” antigens and prevents NK cell attacks on healthy cells.43 In uncontrolled inflammation, SIGLEC-7 is cleaved and released into the plasma.44, 45 Thus elevated plasma SIGLEC-7 may reflect NK-cell activation towards healthy tissues, a potential risk factor for BBB dysfunction and CNS damage.

HE4 and RNAS6, in turn, are involved in antimicrobial responses to pathogens. HE4 is a broad-spectrum protease inhibitor46 protecting against proteolytic microbial virulence. RNAS6 belongs to antimicrobial proteins and peptides (AMPs) that are secreted to blood in response to pathogens47, 48 after infection has breached epithelium.47, 48 The influence of direct antimicrobial responses in dementia pathogenesis is supported by the antimicrobial protection hypothesis,49 which suggests that amyloid β can act as an AMP and protect against pathogens in the CNS.49 However, prolonged activation of this process leads to amyloid deposition.

In combination, these findings support the hypotheses that inflammation and pathogens can cause chronic hyper-activation of innate and adaptive immunity, which then contributes to the development of Alzheimer′s disease and vascular dementia.41, 49, 50

Proteins SAP3, TIMP-4, MIC-1, and OPG have been found to be related to BBB degeneration (Figure 4C). Elevated SAP3 levels have been observed in the cerebrospinal fluid of Alzheimer’s and Parkinson’s disease patients19, 51 and are linked with pericyte degeneration in the retina,52 leading to retinopathy as a complication of diabetes.53 As pericyte degeneration is also observed in BBB breakdown, both mechanisms could play a role in development of dementia. TIMP-4 regulates the activity of multiple metalloproteinases54 that can predispose to BBB degeneration,6 but it is unclear whether elevated TIMP-4 levels are indicators of BBB-degrading processes or damage to the BBB by fibrinogen accumulation. Increased MIC-1 and OPG are also thought to reflect endothelial dysfunction.55-57 CDCP1 is linked with tight junction degeneration58-60 and HE4 is a broad spectrum proteinase inhibitor,46 similar to TIMP-4. MARCKSL1 participates in maintaining endothelia integrity and when cleaved, its elevated plasma levels may reflect endothelial damage.61, 62 SVEP1 can cleave E-selectin that induces apoptosis and dysfunction in endothelium and binds to integrin α9β1 linked with basement membrane dysfunction.63

Damaged BBB passes circulating TREM2, MARCKSL1, CRDL1, SAP3 and NPS-PLA2 into the CNS contributing to reduced neuronal plasticity, activation of microglia, disruptions in lipid metabolism, and increased neuroinflammation, amyloid and tau accumulation, and neurodegeneration.7, 30, 31, 64-67 These findings support the hypothesis that BBB degradation with subsequent passage of toxins and proteins into CNS may play an important aetiological role in dementia.6 We are not aware of previous studies showing that circulating TREM2 already in middle adulthood is associated with increased dementia risk at older ages.

Seven previously identified and three novel proteins are likely to play a role in vascular pathologies (Figure 4D). TIMP-4, SAP3, NPS-PLA2, OPG, and MIC-1 have been linked to dementia and atherosclerosis, remodelling of atherosclerotic plaques, platelet aggregation and thrombosis, and leukocyte invasion into atherosclerotic plaques.54, 55, 57, 68-73 N-terminal pro-BNP is known to be elevated in response to atrial and ventricular overload74 and in plasma and the CNS it can inhibit the activity of neprilysin, an enzyme that reduces amyloid β levels.75 Elevated N-terminal pro-BNP levels are also linked with increased risk of vascular and Alzheimer’s dementia.28, 29, 76, 77 Of the proteins not previously linked to dementia, SVEP1 is known to promote thrombosis,78, 79 and HE4 and CRDL1 participate in angiogenesis in response to ischemia80-82 and might contribute to the abnormal angiogenesis observed in vascular and Alzheimer’s dementia.6, 83 These results provide a variety of mechanisms that could predispose to cerebrovascular dysfunction in dementias.

IGFBP-7 is a protein with high affinity to insulin, and lower affinity to growth factors IGF-1 and IGF-2.84, 85 It is related to reduced central blood flow by restricting free insulin85 in blood which leads to decreased insulin-NO-mediated vasodilation that can predispose to ischemia (Figures 4D and E). IGFBP-7 also prevents insulin from binding to its receptor.85 All these properties are linked to reduced insulin responsiveness indicating that IGFBP-7 may be one of the factors behind central insulin resistance linked with dementia,86 a hypothesis supported by a case-control study showing elevated IGFBP-7 levels in the urine of Alzheimer’s dementia patients.20

Our findings are of potential importance to drug repurposing and research on preventive medication for dementia. Varespladib inhibits the arachidonic acid pathway in inflammation by inhibiting NPS-PLA2 activity, and may counteract inflammation that predisposes to dementia.87 Similarly, itolizumab prevents CDCP1 from binding to CD6, leading to downregulation in T-cell mediated inflammation.88 Randomized control trials on intranasal insulin have shown promising results in improving amyloid and tau profiles and cognition in individuals with cognitive decline or Alzheimer’s dementia.86 Whether more tailored medication that targets IGFBP-7 can be used to ameliorate central insulin resistance should be investigated. Glucose lowering and statin medications linked with reduced inflammation in diabetes are also associated with reduced OPG levels;56, 89, 90 further research should determine whether OPG plays a role in the disease process leading to dementia. Currently available antihypertensive medications can be used to reduce plasma N-terminal pro-BNP levels,74 but whether a drug that directly targets N-terminal pro-BNP is beneficial for cognitive decline and dementia needs to be tested.

This study’s strengths include its large sample size, simultaneous assessment of thousands of proteins, replication of main findings in an independent study population, and the early baseline that allowed assessment of proteins two decades before dementia diagnosis when no changes in plasma amyloid or tau markers were present. Only three dementia cases occurred within the first 10 years of follow-up suggesting low risk of reverse causation. However, observational evidence cannot determine causal associations and therefore our findings should be considered as hypothesis generating. Other limitations include the lack of repeated protein measurements to assess whether changes in protein levels over time are associated with dementia risk; the use of semi-quantitative protein data that cannot determine clinically useful concentrations; and the lack of information on dementia subtypes based on brain imaging or cerebrospinal fluid biomarkers.

In conclusion, using large-scale testing of plasma proteins as long-term risk factors for cognitive decline and dementia, we have provided strong support for the hypothesis that early systemic processes may drive development of dementias. The protein-dementia associations identified and replicated were plausible, involving innate and adaptive immunity, BBB dysfunction, vascular pathology, and central insulin resistance that all can contribute to amyloid and tau deposition, or pathologies that characterise vascular dementia. Our findings point to proteins that may be potential biomarkers and drug targets for dementia, the first crucial step to discover disease-modifying medications that can expand the field beyond amyloid and tau.

Methods

Study design and participants

We used the Whitehall II study as our discovery cohort and the ARIC study as the replication cohort (Figure 1). In 1985-1988, all civil servants aged 35 to 55 years based in 20 departments in London, UK, were invited to participate in the Whitehall II cohort study, and 73% (n=10 308) agreed.91 Blood samples for proteomic analyses were collected from a random subsample of 2274 dementia-free individuals in 1997-99.92 Cognitive performance measurements were conducted at this and four subsequent clinical examinations in 2002-2004, 2007-2009, 2012-13, and 2015-2016. Follow-up started from 1997-99 and ended at death, dementia, or October 2019.

ARIC93 is a community-based cohort study of 15,792 participants from four US communities: Washington County, Maryland; Forsyth County, North Carolina; North-western suburbs of Minneapolis, Minnesota; and Jackson, Mississippi. Participants were aged 44 to 66 years at baseline in 1987-1989. Blood samples for protein analysis were drawn in 1993-1995 and analysed for 11 395 individuals free of dementia. Incident dementia cases were identified during the 1996-1998, 2011-2013 and 2016-2017 clinical examinations and using data from informant interviews, hospital records and death certificates.

Assessment of plasma proteins

In Whitehall II and ARIC, proteins were analysed using the SomaScan version 4 assay. Earlier studies describe performance of the SomaScan assay and the modified aptamer-binding in detail.94-96 In brief, the SomaScan Assay is a multiplexed aptamer-based immunoassay that uses a library of DNA molecules designed to identify specific proteins. The aptamers bind to the target protein in plasma samples and the unspecific fast off rate proteins are washed away. The slow off rate proteins are labelled with biotin and the aptamer-protein complexes incubated in a buffer containing unlabelled polyanionic competitor. This step is analogous to the effect of adding a second antibody to increase specificity in a conventional immunoassay. The aptamer-protein complexes are then recaptured with streptavidin and again washed to remove non-specific aptamer-protein complexes. The aptamers are then released from the proteins, hybridized to complementary sequences on a DNA microarray chip, and quantified by fluorescence. The fluorescence intensity reflects the concentration of each protein. Median intra- and inter-assay coefficients of variation are ∼5% and assay sensitivity is comparable to that of typical immunoassays, with a median lower limit of detection in the femtomolar range.95 Specificity of the modified aptamer reagents is good and has been tested in several ways.92

Cognitive testing

The Whitehall II cognitive test battery covered four domains: executive function, memory, phonemic-, and semantic fluency (Supplementary Methods). Executive function was assessed with the Alice Heim 4-I test, memory with a 20-word free recall test and phonemic and semantic fluency with word and animal name recall tests.97, 98 To minimize measurement error inherent in individual tests, we created a global cognitive score by standardizing each test domain measured in follow-up visits to the baseline score, and then standardizing the summary scores from each phase to the baseline summary score.99 This allowed construction of individual slopes of decline in cognition.

Dementia follow-up

Whitehall II study participants are linked to the National Health Services (NHS) Hospital Episode Statistics (HES) database, and the British National mortality register using individual NHS identification numbers for linkage.100 The NHS provides nearly complete comprehensive health care coverage for all individuals legally resident in the UK. Incident dementia was defined by the WHO International Classification of Diseases, version 10 (ICD-10) codes F00, F01, F03, G30, and G31 and ICD-9 codes 290.0-290.4, 331.0-331.2, 331.82, and 331.9. We also conducted informant interviews and checked participants’ medications at each screening for dementia-related medication. Sensitivity and specificity of dementia assessment based on the HES data is 0.78 and 0.92.101

In ARIC, incident dementias were primarily identified using comprehensive clinical and neuropsychological examinations and informant interviews from visits 5 (2011-2013) and 6 (2016-2017).102, 103 Using all the data available, suspected cases were adjudicated by a committee of clinicians. In between visits, participants were contacted annually via telephone and administered a brief cognitive screener, and their caregivers, a questionnaire. This information, supplemented by surveillance of dementia-related hospital discharge and death certificate codes, was used to estimate the dementia onset date.

Measurement of baseline covariates

In the Whitehall II study, standard self-administered questionnaires provided data on age, sex, ethnicity, socioeconomic status, education, alcohol consumption, and smoking. Experienced clinical nurses measured BMI and systolic blood pressure (SBP) and took blood samples for lipid and glucose measurements.91 Using DNA extracted from whole blood, a standard PCR assay determined APOE genotype using the salting out method.104, 105 Two independent observers read the genotype blind and any discrepancies were resolved by repeating the PCR analysis. In ARIC, baseline covariates included age, sex, and a combined race-study centre variable.

Statistical analysis

We used Spearman correlation to test protein-protein correlations. In the Whitehall II study, individual cognitive measurements were plotted and group means derived with local linear smooth plots for descriptive pourposes.106 The proteins were transformed to normal distribution by inverse rank-based normal transformation. We used age and sex adjusted linear regression to study associations between each protein and the cognitive decline slopes, derived with mixed-effects linear regression, and formed a Manhattan plot based on –log10(p-values). The assumptions of linear regression were assessed by plotting the residuals in residuals versus fitted, normal Q-Q, scale-location, and residual versus leverage plots.106 We used false discovery rate correction (FDR) of 5% to select proteins for further analyses; this translated to p-value cut-off of 0.002. The proteins that survived FDR correction were analysed in age, sex, and ethnicity adjusted Cox regression models107 with incident dementia as the outcome and p-value=0.05 as the cut-off for statistical significance. All the p-values were two-sided. The proportionality assumption in all Cox models was assessed with Schoenfeld residuals and with log-log plots.107 In sensitivity analyses Cox regression was adjusted for age, sex, ethnicity, SBP, antihypertensive medication, BMI, alcohol consumption, smoking, diabetes, socio-economic, and APOE status. We also studied the effect of competing risk of death with the Fine and Gray model.108 To examine reproducibility, proteins that were robustly associated with cognitive decline and dementia in the Whitehall II study were also analysed in the ARIC study. These Cox models with dementia as outcome were adjusted for age, sex and race-study centre.

We searched the Genotype-Tissue Expression (GTEx),109 Human Protein Atlas,110, 111 Database for Annotation, Visualization and Integrated Discovery (DAVID),112, 113 Uniprot,114 and ChEMBL115 databases to characterize protein expression profiles, their cellular localization, and drugs that can target them. We used statistical software R (3.6.0) and Stata (version 16.1 MP; Stata Corp, College Station, TX, USA) for all analyses.

Data Availability

Data, protocols, and other metadata of the Whitehall II and ARIC studies are available to the scientific community. Please refer to the data sharing policies of these studies. Pre-existing data access policies for Whitehall II and ARIC studies specify that research data requests can be submitted to each steering committee; these will be promptly reviewed for confidentiality or intellectual property restrictions and will not unreasonably be refused. Individual-level patient or protein data may further be restricted by consent, confidentiality, or privacy laws/considerations. These policies apply to both clinical and proteomic data.

Contributors

MK, AH, AS-M, GL, EJB, NM and JVL generated the hypothesis and designed the study. JVL, NM, KS and HZ provided initial mechanistic interpretations. JVL, with MK, wrote the first draft of the report. JVL did the primary analyses, with support from NM, and performed literature searches. KW ran the replication analysis. All authors interpreted the data and critically commented and reviewed the report. JVL had full access to pseudonymised data from the Whitehall II study and KW had full access to the ARIC data.

Declaration of interests

In this is an academic–industry partnership project academic collaborators generated the hypothesis and study design and SomaLogic, Inc. provided expertise in plasma proteins and funded SomaScan assays. SAW is employed by SomaLogic, Inc., which has a commercial interest in the results. ASM reports grants from the National Institute on Aging, NIH. RCL reports grants from Alzheimer’s Research UK. RG was as previous Associate Editor for the journal Neurology. HZ reports grants from the Swedish Research Council, the European Research Council, Swedish State Support for Clinical Research, the Alzheimer Drug Discovery Foundation, USA, and the UK Dementia Research Institute. Additionally, HZ reports that he has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. EJB reports grants from British Heart Foundation and UK Research and Innovation. MK reports grants from UK Medical Research Council, US National Institute on Aging, Academy of Finland, Helsinki Institute of Life Science, NordForsk, and the Finnish Work Environment Fund, during the conduct of the study.

Data sharing

Data, protocols, and other metadata of the Whitehall II and ARIC studies are available to the scientific community. Please refer to the data sharing policies of these studies. Pre-existing data access policies for Whitehall II and ARIC studies specify that research data requests can be submitted to each steering committee; these will be promptly reviewed for confidentiality or intellectual property restrictions and will not unreasonably be refused. Individual-level patient or protein data may further be restricted by consent, confidentiality, or privacy laws/considerations. These policies apply to both clinical and proteomic data.

Code availability

This manuscript did not include any custom code and used only pre-existing statistical packages.

Supplement

Supplementary Methods

Cognitive testing

The Whitehall II cognitive test battery covered four domains: executive function, memory, phonemic-, and semantic fluency. Executive function was assessed with the Alice Heim 4-I test, that comprises a series of 65 verbal and mathematical reasoning items of increasing difficulty.97 It tests inductive reasoning, measuring the ability to identify patterns and infer principles and rules, and has time limit of 10 minutes. A 20-word free recall test assessed memory. Participants were presented a list of one or two syllable words at two-second intervals and were then asked to recall in writing as many of the words as possible in any order with two minutes to do so. In assessment of phonemic and semantic fluency98 participants were asked to recall in writing as many words beginning with “s” (phonemic fluency) and as many animal names (semantic fluency) as they could. Time limit for this section was one minute per fluency area.

Based on these measures, we created a global cognitive score by first standardizing the distribution of each test domain measured in follow-up visits to the baseline score to create z-scores with mean 0 and SD 1. We then summed the domain specific scores at each phase and standardized the summary score to the baseline summary score; this approach minimizes measurement error inherent in individual tests.99 After dementia diagnosis, participants were rarely able to complete the cognitive tests and for this reason, their global test score was set to −3SD at phase that followed dementia diagnosis. Based on the global scores we derived a cognitive decline slope for each participant and used this as the outcome.

Acknowledgments

The study was supported by the UK Medical Research Council (S011676, K013351, R024227), the National Institute on Aging (National Institutes of Health; R01AG056477 and R01AG062553), the British Heart Foundation (32334), the Academy of Finland (311492), NordForsk (75021), and SomaLogic, Inc. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from: Median gene-level TPM by tissue dataset from the GTEx Portal on 9/2/2020. JVL was supported by Academy of Finland (311492) and Helsinki Institute of Life Science (H970) and AS-M and AGT were supported by NordForsk (75021, the Nordic Research Programme on Health and Welfare), during the conduct of the study. ASM is supported by the National Institute on Aging, NIH (R01AG062553;R01AG056477). RCL was supported by Alzheimer’s Research UK grant ARUK-NAS2017A-1. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation, USA (201809-2016862), and the UK Dementia Research Institute at UCL. EJB was supported by British Heart Foundation (RG/16/11/32334) and UK Research and Innovation (ES/T014377/1). MK was supported by UK Medical Research Council (MR/S011676, MR/R024227), US National Institute on Aging (R01AG062553, R01AG056477), Academy of Finland (311492), Helsinki Institute of Life Science (H970), NordForsk (75021), and the Finnish Work Environment Fund (190424). The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Neurocognitive data is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD). Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. This study was also supported by contracts K23 AG064122 (Dr. Walker) and K24 AG052573 (Dr. Gottesman) from NIA. UCL and Johns Hopkins University have signed a collaboration agreement with SomaLogic, Inc to conduct SOMAscan of Whitehall and ARIC stored samples at no charge in exchange for the rights to analyse linked Whitehall and ARIC phenotype data.

References

  1. 1.↵
    GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 88–106 (2019).
    OpenUrlCrossRefPubMed
  2. 2.↵
    Jack, C. R., Jr. et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216 (2013).
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Gauthier, S. et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 12, 60–64 (2016).
    OpenUrlCrossRefPubMed
  4. 4.↵
    Knopman, D. S. Lowering of Amyloid-Beta by β-Secretase Inhibitors - Some Informative Failures. N. Engl. J. Med. 380, 1476–1478 (2019).
    OpenUrl
  5. 5.↵
    Brookmeyer, R. & Abdalla, N. Estimation of lifetime risks of Alzheimer’s disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 14, 981–988 (2018).
    OpenUrl
  6. 6.↵
    Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R. & Zlokovic, B. V. Blood-Brain Barrier: From Physiology to Disease and Back. Physiol. Rev. 99, 21–78 (2019).
    OpenUrlCrossRefPubMed
  7. 7.↵
    Shi, Y. & Holtzman, D. M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18, 759–772 (2018).
    OpenUrlCrossRefPubMed
  8. 8.↵
    Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9, e95192 (2014).
    OpenUrlCrossRefPubMed
  9. 9.↵
    Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5, e15004 (2010).
    OpenUrlCrossRefPubMed
  10. 10.↵
    Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 361, 769–773 (2018).
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017).
    OpenUrlCrossRefPubMed
  12. 12.
    Chessum, N. E. A. et al. Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). J. Med. Chem. 61, 918–933 (2018).
    OpenUrlCrossRef
  13. 13.
    Cummings, J., Lee, G., Ritter, A. & Zhong, K. Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement. (N. Y) 4, 195–214 (2018).
    OpenUrlCrossRefPubMed
  14. 14.↵
    Scudellari, M. Protein-slaying drugs could be the next blockbuster therapies. Nature 567, 298–300 (2019).
    OpenUrl
  15. 15.↵
    Katsimpardi, L. et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 344, 630–634 (2014).
    OpenUrlAbstract/FREE Full Text
  16. 16.
    Middeldorp, J. et al. Preclinical Assessment of Young Blood Plasma for Alzheimer Disease. JAMA Neurol. 73, 1325–1333 (2016).
    OpenUrl
  17. 17.↵
    Sha, S. J. et al. Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial. JAMA Neurol. 76, 35–40 (2019).
    OpenUrl
  18. 18.↵
    Hampel, H. et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat. Rev. Neurol. 14, 639–652 (2018).
    OpenUrl
  19. 19.↵
    Heywood, W. E. et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol. Neurodegener 10, 64-015-0059-y (2015).
    OpenUrlCrossRefPubMed
  20. 20.↵
    Yao, F. et al. Urine-Based Biomarkers for Alzheimer’s Disease Identified Through Coupling Computational and Experimental Methods. J. Alzheimers Dis. 65, 421–431 (2018).
    OpenUrlPubMed
  21. 21.↵
    Chai, Y. L. et al. Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia. Medicine (Baltimore) 95, e4566 (2016).
    OpenUrl
  22. 22.
    Jiang, J., Wen, W. & Sachdev, P. S. Macrophage inhibitory cytokine-1/growth differentiation factor 15 as a marker of cognitive ageing and dementia. Curr. Opin. Psychiatry. 29, 181–186 (2016).
    OpenUrl
  23. 23.
    Qin, W. et al. Elevated plasma angiogenesis factors in Alzheimer’s disease. J. Alzheimers Dis. 45, 245–252 (2015).
    OpenUrlCrossRefPubMed
  24. 24.↵
    Emanuele, E. et al. Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer’s disease. Int. J. Mol. Med. 13, 849–853 (2004).
    OpenUrlPubMed
  25. 25.↵
    Jefferson, A. L. et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 68, 1032–1038 (2007).
    OpenUrlCrossRefPubMed
  26. 26.↵
    Moses, G. S. et al. Secretory PLA2-IIA: a new inflammatory factor for Alzheimer’s disease. J. Neuroinflammation 3, 28-2094-3-28 (2006).
    OpenUrlCrossRefPubMed
  27. 27.↵
    Ohara, T. et al. Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study. Ann. Neurol. 85, 47–58 (2019).
    OpenUrl
  28. 28.↵
    Kerola, T. et al. B-type natriuretic peptide as a predictor of declining cognitive function and dementia--a cohort study of an elderly general population with a 5-year follow-up. Ann. Med. 42, 207–215 (2010).
    OpenUrlCrossRefPubMed
  29. 29.↵
    Tynkkynen, J. et al. NT-proBNP and the risk of dementia: a prospective cohort study with 14 years of follow-up. J. Alzheimers Dis. 44, 1007–1013 (2015).
    OpenUrl
  30. 30.↵
    Murphy, A. et al. Induction of protein kinase C substrates, Myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP), by amyloid beta-protein in mouse BV-2 microglial cells. Neurosci. Lett. 347, 9–12 (2003).
    OpenUrlCrossRefPubMed
  31. 31.↵
    Sunohara, J. R., Ridgway, N. D., Cook, H. W. & Byers, D. M. Regulation of MARCKS and MARCKS-related protein expression in BV-2 microglial cells in response to lipopolysaccharide. J. Neurochem. 78, 664–672 (2001).
    OpenUrlCrossRefPubMed
  32. 32.
    Farooqui, A. A. & Horrocks, L. A. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7, 232–245 (2001).
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.
    Fuchs, T. et al. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study. Aging Cell. 12, 882–889 (2013).
    OpenUrlCrossRefPubMed
  34. 34.
    Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A. & Breit, S. N. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. Cell. Metab. 28, 353–368 (2018).
    OpenUrlCrossRef
  35. 35.↵
    Whelan, C. D. et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. Acta Neuropathol. Commun. 7, 169-019-0795-2 (2019).
    OpenUrl
  36. 36.↵
    Gilgés, D. et al. Polydom: a secreted protein with pentraxin, complement control protein, epidermal growth factor and von Willebrand factor A domains. Biochem. J. 352 Pt 1, 49–59 (2000).
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Van Itallie, C. M. et al. MARCKS-related protein regulates cytoskeletal organization at cell-cell and cell-substrate contacts in epithelial cells. J. Cell. Sci. 131, jcs210237. doi: 10.1242/jcs.210237 (2018).
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Huber-Lang, M., Lambris, J. D. & Ward, P. A. Innate immune responses to trauma. Nat. Immunol. 19, 327–341 (2018).
    OpenUrl
  39. 39.↵
    Ennerfelt, H. E. & Lukens, J. R. The role of innate immunity in Alzheimer’s disease. Immunol. Rev. (2020).
  40. 40.↵
    Morgan, A. R. et al. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimers Dement. 15, 776–787 (2019).
    OpenUrlPubMed
  41. 41.↵
    Akiyama, H. et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging 21, 383–421 (2000).
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Enyindah-Asonye, G. et al. CD318 is a ligand for CD6. Proc. Natl. Acad. Sci. U. S. A. 114, E6912–E6921 (2017).
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    Fong, J. J. et al. Siglec-7 engagement by GBS Î2-protein suppresses pyroptotic cell death of natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 115, 10410–10415 (2018).
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    Varchetta, S. et al. Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages. Retrovirology 10, 154-4690-10-154 (2013).
    OpenUrlCrossRefPubMed
  45. 45.↵
    Varchetta, S. et al. Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. Gut 65, 1998–2006 (2016).
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    LeBleu, V. S. et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat. Med. 19, 227–231 (2013).
    OpenUrlCrossRefPubMed
  47. 47.↵
    Becknell, B. et al. Ribonucleases 6 and 7 have antimicrobial function in the human and murine urinary tract. Kidney Int. 87, 151–161 (2015).
    OpenUrlCrossRefPubMed
  48. 48.↵
    Lu, L. et al. Human Antimicrobial RNases Inhibit Intracellular Bacterial Growth and Induce Autophagy in Mycobacteria-Infected Macrophages. Front. Immunol. 10, 1500 (2019).
    OpenUrl
  49. 49.↵
    Moir, R. D., Lathe, R. & Tanzi, R. E. The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement. 14, 1602–1614 (2018).
    OpenUrlCrossRef
  50. 50.↵
    Readhead, B. et al. Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron 99, 64-82.e7 (2018).
    OpenUrlCrossRefPubMed
  51. 51.↵
    Sjödin, S. et al. Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease. Alzheimers Res. Ther. 11, 82-019-0533-9 (2019).
    OpenUrl
  52. 52.↵
    Masson, E., Wiernsperger, N., Lagarde, M. & El Bawab, S. Involvement of gangliosides in glucosamine-induced proliferation decrease of retinal pericytes. Glycobiology 15, 585–591 (2005).
    OpenUrlCrossRefPubMed
  53. 53.↵
    Caseiro, A. et al. Pursuing type 1 diabetes mellitus and related complications through urinary proteomics. Transl. Res. 163, 188–199 (2014).
    OpenUrlCrossRefPubMed
  54. 54.↵
    Brew, K., Dinakarpandian, D. & Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267–283 (2000).
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    Lind, L. et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur. Heart J. 30, 2346–2353 (2009).
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    Kadoglou, N. P. et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J. Vasc. Surg. 51, 114–121 (2010).
    OpenUrlCrossRefPubMed
  57. 57.↵
    Pérez de Ciriza, C., Lawrie, A. & Varo, N. Osteoprotegerin in Cardiometabolic Disorders. Int. J. Endocrinol. 2015, 564934 (2015).
    OpenUrlCrossRefPubMed
  58. 58.↵
    Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11–25 (1992).
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.
    Windham, T. C. et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 21, 7797–7807 (2002).
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    Thomas, S. M. & Brugge, J. S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13, 513–609 (1997).
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    Braun, T., McIlhinney, R. A. & VergÃ‥res, G. Myristoylation-dependent N-terminal cleavage of the myristoylated alanine-rich C kinase substrate (MARCKS) by cellular extracts. Biochimie 82, 705–715 (2000).
    OpenUrlCrossRefPubMed
  62. 62.↵
    Guo, Y. et al. Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. Mol. Cell. Proteomics 6, 689–696 (2007).
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    Schwanzer-Pfeiffer, D., Rossmanith, E., Schildberger, A. & Falkenhagen, D. Characterization of SVEP1, KIAA, and SRPX2 in an in vitro cell culture model of endotoxemia. Cell. Immunol. 263, 65–70 (2010).
    OpenUrlCrossRefPubMed
  64. 64.↵
    Blanco-Suarez, E., Liu, T. F., Kopelevich, A. & Allen, N. J. Astrocyte-Secreted Chordin-like 1 Drives Synapse Maturation and Limits Plasticity by Increasing Synaptic GluA2 AMPA Receptors. Neuron 100, 1116-1132.e13 (2018).
    OpenUrl
  65. 65.
    Sun, M. et al. Presynaptic contributions of chordin to hippocampal plasticity and spatial learning. J. Neurosci. 27, 7740–7750 (2007).
    OpenUrlAbstract/FREE Full Text
  66. 66.
    Gruber, A., Mancek, M., Wagner, H., Kirschning, C. J. & Jerala, R. Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J. Biol. Chem. 279, 28475–28482 (2004).
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    Villanueva, E. B., Little, J. P., Lambeau, G. & Klegeris, A. Secreted phospholipase A(2) group IIA is a neurotoxin released by stimulated human glial cells. Mol. Cell. Neurosci. 49, 430–438 (2012).
    OpenUrlPubMed
  68. 68.↵
    Ibeas, E., Fuentes, L., MartÍn, R., Hernández, M. & Nieto, M. L. Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis. Cardiovasc. Res. 81, 54–63 (2009).
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.
    Hazen, S. L., Ford, D. A. & Gross, R. W. Activation of a membrane-associated phospholipase A2 during rabbit myocardial ischemia which is highly selective for plasmalogen substrate. J. Biol. Chem. 266, 5629–5633 (1991).
    OpenUrlAbstract/FREE Full Text
  70. 70.
    Yanai, H., Yoshid, H., Tomono, Y., Tada, N. & Chiba, H. The Possible Contribution of a General Glycosphingolipid Transporter, GM2 Activator Protein, to Atherosclerosis. (2006).
  71. 71.
    Melendez-Zajgla, J., Del Pozo, L., Ceballos, G. & Maldonado, V. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol. Cancer. 7, 85-4598-7-85 (2008).
    OpenUrlCrossRefPubMed
  72. 72.
    Santos-MartÍnez, M. J., Medina, C., Jurasz, P. & Radomski, M. W. Role of metalloproteinases in platelet function. Thromb. Res. 121, 535–542 (2008).
    OpenUrlCrossRefPubMedWeb of Science
  73. 73.↵
    Tummalapalli, C. M., Heath, B. J. & Tyagi, S. C. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J. Cell. Biochem. 80, 512–521 (2001).
    OpenUrlCrossRefPubMedWeb of Science
  74. 74.↵
    Singh, J. S. S. et al. Sacubitril/valsartan: beyond natriuretic peptides. Heart 103, 1569–1577 (2017).
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    Hu, W. T. et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897–905 (2012).
    OpenUrlCrossRef
  76. 76.↵
    Hilal, S. et al. Markers of cardiac dysfunction in cognitive impairment and dementia. Medicine (Baltimore) 94, e297 (2015).
    OpenUrlCrossRefPubMed
  77. 77.↵
    Kondziella, D., Göthlin, M., Fu, M., Zetterberg, H. & Wallin, A. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. Neuroreport 20, 825–827 (2009).
    OpenUrlCrossRefPubMedWeb of Science
  78. 78.↵
    Dhanesha, N. et al. Targeting myeloid-cell specific integrin α9β1 inhibits arterial thrombosis in mice. Blood 135, 857–861 (2020).
    OpenUrl
  79. 79.↵
    Dhanesha, N. et al. Targeting Myeloid-Specific Integrin α9β1 Improves Short-and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation. Circ. Res. 126, 1779–1794 (2020).
    OpenUrl
  80. 80.↵
    Sakuta, H. et al. Ventroptin: a BMP-4 antagonist expressed in a double-gradient pattern in the retina. Science 293, 111–115 (2001).
    OpenUrlAbstract/FREE Full Text
  81. 81.
    Kane, R., Godson, C. & O’Brien, C. Chordin-like 1, a bone morphogenetic protein-4 antagonist, is upregulated by hypoxia in human retinal pericytes and plays a role in regulating angiogenesis. Mol. Vis. 14, 1138–1148 (2008).
    OpenUrlPubMed
  82. 82.↵
    James, N. E. et al. The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes. Sci. Rep. 10, 8558-020-65353-x (2020).
    OpenUrl
  83. 83.↵
    Iadecola, C. The pathobiology of vascular dementia. Neuron 80, 844–866 (2013).
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.↵
    Evdokimova, V. et al. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci. Signal. 5, ra92 (2012).
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    Yamanaka, Y., Wilson, E. M., Rosenfeld, R. G. & Oh, Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J. Biol. Chem. 272, 30729–30734 (1997).
    OpenUrlAbstract/FREE Full Text
  86. 86.↵
    Kellar, D. & Craft, S. Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. (2020).
  87. 87.↵
    Nicholls, S. J. et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311, 252–262 (2014).
    OpenUrlCrossRefPubMedWeb of Science
  88. 88.↵
    Dogra, S., Uprety, S. & Suresh, S. H. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. Expert Opin. Biol. Ther. 17, 395–402 (2017).
    OpenUrl
  89. 89.↵
    Nybo, M. et al. Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. Basic Clin. Pharmacol. Toxicol. 109, 481–485 (2011).
    OpenUrlCrossRefPubMed
  90. 90.↵
    Esteghamati, A., Afarideh, M., Feyzi, S., Noshad, S. & Nakhjavani, M. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Diabetes Metab. Syndr. 9, 258–265 (2015).
    OpenUrl
  91. 91.↵
    Marmot, M. G. et al. Health inequalities among British civil servants: the Whitehall II study. Lancet 337, 1387–1393 (1991).
    OpenUrlCrossRefPubMedWeb of Science
  92. 92.↵
    Williams, S. A. et al. Plasma protein patterns as comprehensive indicators of health. Nat. Med. 25, 1851–1857 (2019).
    OpenUrlCrossRef
  93. 93.↵
    The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am. J. Epidemiol. 129, 687–702 (1989).
    OpenUrlCrossRefPubMed
  94. 94.↵
    Kim, C. H. et al. Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. Sci. Rep. 8, 8382-018-26640-w (2018).
    OpenUrl
  95. 95.↵
    Candia, J. et al. Assessment of Variability in the SOMAscan Assay. Sci. Rep. 7, 14248-017-14755-5 (2017).
    OpenUrlCrossRefPubMed
  96. 96.↵
    Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5, e15004 (2010).
    OpenUrlCrossRefPubMed
  97. 97.↵
    Heim, A. AH 4 group test of general intelligence. NFER-Nelson Publishing Company (1970).
  98. 98.↵
    Borkowski, J., Benton, A. & Spreen, O. Word fluency and brain damage. Neuropsychologia 5, 135–40 (1967).
    OpenUrlCrossRefWeb of Science
  99. 99.↵
    Wilson, R. S., Leurgans, S. E., Boyle, P. A., Schneider, J. A. & Bennett, D. A. Neurodegenerative basis of age-related cognitive decline. Neurology 75, 1070–1078 (2010).
    OpenUrlCrossRefPubMed
  100. 100.↵
    Kivimaki, M. et al. Validity of Cardiovascular Disease Event Ascertainment Using Linkage to UK Hospital Records. Epidemiology 28, 735–739 (2017).
    OpenUrl
  101. 101.↵
    Sommerlad, A. et al. Accuracy of general hospital dementia diagnoses in England: Sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016. Alzheimers Dement. 14, 933–943 (2018).
    OpenUrlCrossRefPubMed
  102. 102.↵
    Walker, K. A. et al. Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. JAMA 322, 535–545 (2019).
    OpenUrlPubMed
  103. 103.↵
    Gottesman, R. F. et al. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol. 74, 1246–1254 (2017).
    OpenUrl
  104. 104.↵
    Bolla, M. K., Wood, N. & Humphries, S. E. Rapid determination of apolipoprotein E genotype using a heteroduplex generator. J. Lipid Res. 40, 2340–2345 (1999).
    OpenUrlAbstract/FREE Full Text
  105. 105.↵
    Miller, S. A., Dykes, D. D. & Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).
    OpenUrlCrossRefPubMedWeb of Science
  106. 106.↵
    Gareth, J., Witten, D., Hastie, T. & Tibshirani, R. in An Introduction to Statistical Learning: With Applications in R. (Springer Publishing Company, Incorporated., 2014).
  107. 107.↵
    Cox, D. R. Regression Models and Life-Tables. Journal of the Royal Statistical Society. Series B (Methodological) 34, 187–220 (1972).
    OpenUrlWeb of Science
  108. 108.↵
    Fine JP, G. R. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association., 496–509 (1999).
  109. 109.↵
  110. 110.↵
  111. 111.↵
    Uhlén, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
    OpenUrlAbstract/FREE Full Text
  112. 112.↵
    Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).
    OpenUrlCrossRefPubMedWeb of Science
  113. 113.↵
    Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
    OpenUrlCrossRefPubMedWeb of Science
  114. 114.↵
    UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506–D515 (2019).
    OpenUrlCrossRefPubMed
  115. 115.↵
    Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–D954 (2017).
    OpenUrlCrossRefPubMed
Back to top
Posted November 20, 2020.
Download PDF
Data/Code
Email
Association of plasma proteins with rate of cognitive decline and dementia: 20-year follow-up of the Whitehall II and ARIC cohort studies
Joni V. Lindbohm, Nina Mars, Keenan A. Walker, Archana Singh-Manoux, Gill Livingston, Eric J. Brunner, Pyry N. Sipilä, Kalle Saksela, Jane E. Ferrie, Ruth Lovering, Stephen A. Williams, Aroon D. Hingorani, Rebecca F. Gottesman, Henrik Zetterberg, Mika Kivimäki
medRxiv 2020.11.18.20234070; doi: https://doi.org/10.1101/2020.11.18.20234070
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area